(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 1.61% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Enanta Pharmaceuticals's revenue in 2024 is $73,622,000.On average, 4 Wall Street analysts forecast ENTA's revenue for 2024 to be $1,417,662,421, with the lowest ENTA revenue forecast at $1,253,280,433, and the highest ENTA revenue forecast at $1,535,924,366. On average, 5 Wall Street analysts forecast ENTA's revenue for 2025 to be $1,646,358,597, with the lowest ENTA revenue forecast at $1,053,779,513, and the highest ENTA revenue forecast at $2,368,200,737.
In 2026, ENTA is forecast to generate $1,587,968,084 in revenue, with the lowest revenue forecast at $546,882,161 and the highest revenue forecast at $2,473,134,413.